2. Academic Validation
  3. Discovery of first-in-class inhibitors of ASH1L histone methyltransferase with anti-leukemic activity

Discovery of first-in-class inhibitors of ASH1L histone methyltransferase with anti-leukemic activity

  • Nat Commun. 2021 May 14;12(1):2792. doi: 10.1038/s41467-021-23152-6.
David S Rogawski  # 1,  Jing Deng  # 1,  Hao Li  # 1,  Hongzhi Miao 1,  Dmitry Borkin 1,  Trupta Purohit 1,  Jiho Song 1,  Jennifer Chase 2,  Shuangjiang Li 1,  Juliano Ndoj 1,  Szymon Klossowski 1,  EunGi Kim 1,  Fengbiao Mao 1,  Bo Zhou 1,  James Ropa 1 3,  Marta Z Krotoska 1,  Zhuang Jin 1,  Patricia Ernst 4,  Xiaomin Feng 5,  Gang Huang 5,  Kenichi Nishioka 6,  Samantha Kelly 7,  Miao He 8,  Bo Wen 8,  Duxin Sun 8,  Andrew Muntean 1,  Yali Dou 1,  Ivan Maillard 2 7,  Tomasz Cierpicki 9,  Jolanta Grembecka 10
Affiliations

Affiliations

  • 1 Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
  • 2 Life Sciences Institute, University of Michigan, Ann Arbor, MI, USA.
  • 3 Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA.
  • 4 Department of Pediatrics, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.
  • 5 Department of Pathology and Laboratory Medicine, Cincinnati Children's Hospital, Cincinnati, OH, USA.
  • 6 Department of Internal Medicine Musashimurayama Hospital, Enoki 1-1-5, Musashimurayama, Tokyo, Japan.
  • 7 Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • 8 College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
  • 9 Department of Pathology, University of Michigan, Ann Arbor, MI, USA. tomaszc@umich.edu.
  • 10 Department of Pathology, University of Michigan, Ann Arbor, MI, USA. jolantag@med.umich.edu.
  • # Contributed equally.
PMID: 33990599 DOI: 10.1038/s41467-021-23152-6
Abstract

ASH1L Histone Methyltransferase plays a crucial role in the pathogenesis of different diseases, including acute leukemia. While ASH1L represents an attractive drug target, developing ASH1L inhibitors is challenging, as the catalytic SET domain adapts an inactive conformation with autoinhibitory loop blocking the access to the active site. Here, by applying fragment-based screening followed by medicinal chemistry and a structure-based design, we developed first-in-class small molecule inhibitors of the ASH1L SET domain. The crystal structures of ASH1L-inhibitor complexes reveal compound binding to the autoinhibitory loop region in the SET domain. When tested in MLL leukemia models, our lead compound, AS-99, blocks cell proliferation, induces Apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo. This work validates the ASH1L SET domain as a druggable target and provides a chemical probe to further study the biological functions of ASH1L as well as to develop therapeutic agents.

Figures
Products